Search Results - "Greil, R"

Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study by Gianni, L., Huang, C.S., Egle, D., Bermejo, B., Zamagni, C., Thill, M., Anton, A., Zambelli, S., Bianchini, G., Russo, S., Ciruelos, E.M., Greil, R., Semiglazov, V., Colleoni, M., Kelly, C., Mariani, G., Del Mastro, L., Maffeis, I., Valagussa, P., Viale, G.

“…High-risk triple-negative breast cancers (TNBCs) are characterized by poor prognosis, rapid progression to metastatic stage and onset of resistance to…”
Get full text

Primary surgery versus no surgery in synchronous metastatic breast cancer: patient-reported quality-of-life outcomes of the prospective randomized multicenter ABCSG-28 Posytive Trial by Bjelic-Radisic, V, Fitzal, F, Knauer, M, Steger, G, Egle, D, Greil, R, Schrenk, P, Balic, M, Singer, Ch, Exner, R, Soelkner, L, Gnant, Michael

“…The ABCSG-28 trial compared primary surgery followed by systemic therapy versus primary systemic therapy without surgery in patients with de novo stage IV BC…”
Get full text

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials by Coleman, R, Powles, T, Paterson, A, Gnant, M, Anderson, S, Diel, I, Gralow, J, von Minckwitz, G, Moebus, V, Bergh, J, Pritchard, KI, Bliss, J, Cameron, D, Evans, V, Pan, H, Peto, R, Bradley, R, Gray, R, Bartsch, R, Dubsky, P, Fesl, C, Fohler, H, Greil, R, Jakesz, R, Lang, A, Luschin-Ebengreuth, G, Marth, C, Mlineritsch, B, Samonigg, H, Singer, CF, Steger, GG, Stoger, H, Olivotto, I, Ragaz, J, Christiansen, P, Ejlertsen, B, Ewertz, M, Jensen, MB, Moller, S, Mouridsen, HT, Eiermann, W, Hilfrich, J, Jonat, W, Kaufmann, M, Kreienberg, R, Schumacher, M, Blohmer, JU, Costa, SD, Eidtmann, H, Gerber, B, Jackisch, C, Loibl, S, Dafni, U, Markopoulos, C, Blomqvist, C, Saarto, T, Ahn, JH, Jung, KH, Perrone, F, Bass, G, Brown, A, Bryant, J, Costantino, J, Dignam, J, Fisher, B, Geyer, C, Mamounas, EP, Paik, S, Redmond, C, Swain, S, Wickerham, L, Wolmark, N, Perez, E, Ingle, JN, Suman, VJ, Hadji, P, A'Hern, R, Dowsett, M, Makris, A, Parton, M, Pennert, K, Powles, TJ, Smith, IE, Yarnold, JR, Clack, G, Van Poznak, C, Safra, T, Bell, R, Coleman, RE, Dodwell, D, Hinsley, S, Marshall, HC, Solomayer, E, Fehm, T, Lester, J, Winter, MC, Horsman, JM, Aft, R, Brufsky, AM, Llombart, HA

“…Summary Background Bisphosphonates have profound effects on bone physiology, and could modify the process of metastasis. We undertook collaborative…”
Get full text

Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone by Gnant, M., Filipits, M., Greil, R., Stoeger, H., Rudas, M., Bago-Horvath, Z., Mlineritsch, B., Kwasny, W., Knauer, M., Singer, C., Jakesz, R., Dubsky, P., Fitzal, F., Bartsch, R., Steger, G., Balic, M., Ressler, S., Cowens, J.W., Storhoff, J., Ferree, S., Schaper, C., Liu, S., Fesl, C., Nielsen, T.O.

“…PAM50 is a 50-gene test that is designed to identify intrinsic breast cancer subtypes and generate a Risk of Recurrence (ROR) score. It has been developed to…”
Get full text

EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer by Dubsky, P., Filipits, M., Jakesz, R., Rudas, M., Singer, C.F., Greil, R., Dietze, O., Luisser, I., Klug, E., Sedivy, R., Bachner, M., Mayr, D., Schmidt, M., Gehrmann, M.C., Petry, C., Weber, K.E., Kronenwett, R., Brase, J.C., Gnant, M.

“…In early estrogen receptor (ER)-positive/HER2-negative breast cancer, the decision to administer chemotherapy is largely based on prognostic criteria. The…”
Get full text

Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12 by Gnant, M., Mlineritsch, B., Stoeger, H., Luschin-Ebengreuth, G., Knauer, M., Moik, M., Jakesz, R., Seifert, M., Taucher, S., Bjelic-Radisic, V., Balic, M., Eidtmann, H., Eiermann, W., Steger, G., Kwasny, W., Dubsky, P., Selim, U., Fitzal, F., Hochreiner, G., Wette, V., Sevelda, P., Ploner, F., Bartsch, R., Fesl, C., Greil, R.

“…These final results from ABCSG-12 confirm that twice-yearly ZOL safely enhances the efficacy of adjuvant endocrine therapy. Tamoxifen together with Goserelin…”
Get full text

The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients by Dubsky, P, Brase, J C, Jakesz, R, Rudas, M, Singer, C F, Greil, R, Dietze, O, Luisser, I, Klug, E, Sedivy, R, Bachner, M, Mayr, D, Schmidt, M, Gehrmann, M C, Petry, C, Weber, K E, Fisch, K, Kronenwett, R, Gnant, M, Filipits, M

“…Background: ER+/HER2− breast cancers have a proclivity for late recurrence. A personalised estimate of relapse risk after 5 years of endocrine treatment can…”
Get full text

Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER) by Moehler, M., Maderer, A., Thuss-Patience, P.C., Brenner, B., Meiler, J., Ettrich, T.J., Hofheinz, R.-D., Al-Batran, S.E., Vogel, A., Mueller, L., Lutz, M.P., Lordick, F., Alsina, M., Borchert, K., Greil, R., Eisterer, W., Schad, A., Slotta-Huspenina, J., Van Cutsem, E., Lorenzen, S.

“…Palliative chemotherapy of advanced oesophageal squamous cell cancer (ESCC) consists of cisplatin/5-fluorouracil (CF) to target epidermal growth factor…”
Get full text

How I treat diffuse large B-cell lymphoma by Melchardt, T., Egle, A., Greil, R.

“…Diffuse large B-cell lymphoma (DLBCL) is usually treated with chemoimmunotherapy in curative intention at initial diagnosis. Novel agents have improved the…”
Get full text

Association between antibiotics use and outcome in patients with NSCLC treated with immunotherapeutics by Huemer, F., Rinnerthaler, G., Lang, D., Hackl, H., Lamprecht, B., Greil, R.

Get full text

Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype by Gnant, M., Sestak, I., Filipits, M., Dowsett, M., Balic, M., Lopez-Knowles, E., Greil, R., Dubsky, P., Stoeger, H., Rudas, M., Jakesz, R., Ferree, S., Cowens, J.W., Nielsen, T., Schaper, C., Fesl, C., Cuzick, J.

“…In the adjuvant treatment of hormone receptor-positive (HR+) breast cancer, variables like tumour size, grade and nodal status have great impact on therapy…”
Get full text

PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2- disease: results from 1204 patients in the randomized ABCSG-8 trial by Fitzal, F, Filipits, M, Fesl, C, Rudas, M, Greil, R, Balic, M, Moinfar, F, Herz, W, Dubsky, P, Bartsch, R, Ferree, S, Schaper, C, Gnant, M

“…The aim of this study was to investigate whether the PAM-50-based 46-gene assay carries prognostic value for risk of local recurrence of breast cancer. The…”
Get full text

KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) by Burtness, B., Harrington, K.J., Greil, R., Soulières, D., Tahara, M., De Castro, G., Psyrri, A., Baste Rotllan, N., Neupane, P.C., Bratland, Å, Fuereder, T., Hughes, B.G.M., Mesia, R., Ngamphaiboon, N., Rordorf, T., Wan Ishak, W.Z., Roy, A., Cheng, J., Jin, F., Rischin, D.

Get full text

Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study by Ludwig, H, Weisel, K, Petrucci, M T, Leleu, X, Cafro, A M, Garderet, L, Leitgeb, C, Foa, R, Greil, R, Yakoub-Agha, I, Zboralski, D, Vauléon, S, Dümmler, T, Beyer, D, Kruschinski, A, Riecke, K, Baumann, M, Engelhardt, M

Get full text

Response to Rituximab after Failure of Cyclophosphamide in the Induction Treatment in a Patient with cANCA-associated Vasculitis and Pachymeningitis: a Case Report by Psenak, O., Greil, R.

“…A 36-year-old male patient who originally presented with recurrent inflammations in the mastoid, otitis media and peripheral facial paralysis was diagnosed…”
Get full text

The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial by Fitzal, F, Filipits, M, Rudas, M, Greil, R, Dietze, O, Samonigg, H, Lax, S, Herz, W, Dubsky, P, Bartsch, R, Kronenwett, R, Gnant, M

“…Background: The aim of this study was to examine whether EndoPredict (EP), a novel genomic expression test, is effective in predicting local recurrence…”
Get full text

Hedgehog/GLI and PI3K signaling in the initiation and maintenance of chronic lymphocytic leukemia by Kern, D, Regl, G, Hofbauer, S W, Altenhofer, P, Achatz, G, Dlugosz, A, Schnidar, H, Greil, R, Hartmann, T N, Aberger, F

“…The initiation and maintenance of a malignant phenotype requires complex and synergistic interactions of multiple oncogenic signals. The Hedgehog (HH)/GLI…”
Get full text

Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma by Weiss, L., Melchardt, T., Habringer, S., Boekstegers, A., Hufnagl, C., Neureiter, D., Hopfinger, G., Greil, R., Egle, A.

“…Obesity is a well-known risk factor for the development of several types of cancer including lymphomas, but its influence on the course of disease is fairly…”
Get full text

Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patients by Matikas, A., Foukakis, T., Moebus, V., Greil, R., Bengtsson, N. -O., Steger, G.G., Untch, M., Johansson, H., Hellström, M., Malmström, P., Gnant, M., Loibl, S., Bergh, J.

“…Adjuvant chemotherapy (ACT) for breast cancer improves relapse-free survival (BCRFS) and overall survival. Differences in terms of efficacy and toxicity could…”
Get full text

The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial by Gnant, M, Pfeiler, G, Stöger, H, Mlineritsch, B, Fitzal, F, Balic, M, Kwasny, W, Seifert, M, Stierer, M, Dubsky, P, Greil, R, Steger, G, Samonigg, H, Fesl, C, Jakesz, R

“…Background: We investigated whether body mass index (BMI) can be used as a predictive parameter indicating patients who benefit from extended aromatase…”
Get full text